Enadenotucirev
Species of oncocytic human adenovirus
From Wikipedia, the free encyclopedia
Enadenotucirev is an investigational oncolytic virus that is in clinical trials for various cancers.[1]
| Enadenotucirev | |
|---|---|
Virus classification  | |
| (unranked): | Virus |
| Realm: | Varidnaviria |
| Kingdom: | Bamfordvirae |
| Phylum: | Preplasmiviricota |
| Class: | Pharingeaviricetes |
| Order: | Rowavirales |
| Family: | Adenoviridae |
| Genus: | Mastadenovirus |
| Species: | Human mastadenovirus B |
It is an oncolytic A11/Ad3 Chimeric Group B Adenovirus, previously described as ColoAd1.[2]
Enadenotucirev has also been modified with additional genes using the tumor-specific immuno-gene therapy (T-SIGn) platform to develop novel cancer gene therapy agents.[citation needed]
The T-SIGn vectors at clinical study stage are:[citation needed]
- NG-350A: This vector contains two transgenes expressing the heavy and light chains for a secreted CD40 agonist monoclonal antibody.
- NG-641: This vector contains four transgenes expressing secreted Interferon alpha, the chemokines CXCL9, CXCL10 and an anti-FAP/anti-CD3 bispecific T-cell activator
In Jan 2015 the European Medicines Agency's (EMA) Committee for Orphan Medical Products (COMP) designated enadenotucirev as an orphan medicinal product for the treatment of ovarian cancer.[3]
Clinical trials
Two clinical trials have been completed with enadenotucirev. The EVOLVE study [4] and the MOA study.[5]
As of June 2019[update], there are two active phase 1 trials: OCTAVE (in ovarian cancer)[6] and SPICE (in multiple solid tumor indications) [7]
Of the T-SIGn viruses, NG-350A has an ongoing clinical study.[8]
